Haixiang Pharmaceutical (002099.SZ): Currently, the hedging ratio continues to remain low, and the impact on the company's future performance will decrease

Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Form shows that the company's foreign export business is high, and the main purpose of the company hedging a certain percentage of US dollar assets is to reduce the uncertain impact of large exchange rate fluctuations and improve the company's resilience to risks. Currently, the hedging ratio continues to remain low, and the impact on the company's future performance will decrease.

Gelonghui FinanceMay 20 21:41 ET

Haixiang Pharmaceutical (002099.SZ): The company will not build a large-scale sales team in pharmaceutical-side sales

Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Sheet shows that the company will not build a large-scale sales team in pharmaceutical-side sales, and will mainly expand market sales by participating in collection and cooperating with other sales companies. The company successfully won the bid for the ninth batch of voglevosaccharide tablets approved last year. Supply has already begun this year, and sales markets outside of collection are also being developed simultaneously. Pantoprazole sodium enteric tablets, which passed the consistency evaluation last year, are also on sale, and this year's formulation revenue should increase by magnitude. In addition, reglinide tablets are in the supplementation phase, and a total of 5 hypoglycemic and psychotropic products are being developed

Gelonghui FinanceMay 20 21:40 ET

Haixiang Pharmaceutical (002099.SZ): Currently, the company's CMO/CDMO business strategic customer stock business maintains a good growth momentum

Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Form shows that the company set up a new major customer department, and the chairman personally led the team to connect with potential customers to dig deeper into strategic customer project cooperation. At the same time, it quickly responds to customer needs with the company's own advantages such as quality system, process optimization ability, and commercial large-scale production capacity, and provides strong support for customer project registration and certification, and achieve rapid commercial implementation of the project. At present, the company's CMO/CDMO business strategic customer stock business maintains a good growth momentum, and new strategic customer projects continue to advance

Gelonghui FinanceMay 20 21:38 ET

Haixiang Pharmaceutical (002099.SZ): As of May 10, the number of shareholders of the company was 29,008

Gelonghui, May 13 | Haixiang Pharmaceutical (002099.SZ) said on the investor interactive platform that as of May 10, the number of shareholders of the company was 29,008.

Gelonghui FinanceMay 13 03:18 ET

Chairman of Haixiang Pharmaceutical (002099.SZ) increased his total holdings by 696,500 shares

Haixiang Pharmaceutical (002099.SZ) issued an announcement. As of May 2, 2024, Wang Yang, the chairman of the company, had surged...

Zhitong FinanceMay 6 04:39 ET

Haixiang Pharmaceutical (002099.SZ): The repurchase was completed with a cumulative cost of 151 million yuan to repurchase 31.478,500 shares

Gelonghui, May 6, 丨 Haixiang Pharmaceutical (002099.SZ) announced that as of May 1, 2024, the repurchase period has expired, and the share repurchase plan has been implemented. The actual repurchase range of this repurchase was from February 5, 2024 to April 30, 2024. The company actually repurchased 31.478,500 shares of the company's total share capital, and the highest transaction price was 6.37 yuan/share. The minimum transaction price was 3.98 yuan/share, and the total transaction amount was 151 million yuan (including transaction fees).

Gelonghui FinanceMay 6 04:04 ET